Rocket, Labs

Rocket Lab's Reliability Story Cuts Both Ways After a Split Week

Published on 11/16/2026 at 16:32 | Editorial boerse-global.de
Rocket Lab's 100th Electron flight met its orbit, but a rival's anomaly and Wall Street target cuts kept the focus on Neutron's 2027 slip.
Rocket Lab's Reliability Story Cuts Both Ways After a Split Week Illustration mit AI erstellt.

Rocket Lab's 100th Electron launch should have been the story of the week. Instead, it landed alongside a rival's failure and a pair of Wall Street target cuts, leaving investors to weigh a proven small-rocket business against a heavy development bet whose first flight keeps slipping.

The milestone mission lifted off from Launch Complex 1 in New Zealand, carrying the YAMATSUMI-II radar satellite to orbit for iQPS. According to Rocket Lab, no other commercially developed rocket has reached 100 launches faster. More telling than the round number is the repeat business behind it: the flight was the eleventh Electron mission for iQPS, and the company says every one of that customer's missions since 2023 has succeeded. Seven further Electron launches are on the books for iQPS through 2030, and CEO Peter Beck has said the next 100 Electron flights are already booked.

A Rival's Bad Day, Felt in the Share Price

The glow did not carry over to the market. On Saturday, a Vulcan mission flown by competitor ULA suffered an anomaly that left 40 Amazon Leo satellites short of their intended orbit; ULA is investigating. Benzinga reported pre-market selling pressure on Rocket Lab in the wake of that failure, even though there is no technical link between the two rocket programmes. The distinction matters: Electron executed its latest contract cleanly, while Vulcan's setback speaks to the industry-wide execution risk of the launch business — not to a defect in Rocket Lab's own hardware.

Should investors sell immediately? Or is it worth buying Rocket Lab?

Wall Street had already been trimming its expectations. Morgan Stanley's Kristine Liwag cut her price target to $103 from $105 on Wednesday while keeping an "Overweight" rating, according to media reports. Piper Sandler had moved earlier, lowering its target to $58 from $83 on 10 November following quarterly results, with a "Neutral" rating unchanged. Both houses adjusted their numbers without touching their recommendations. The stock shed 3.8% on Friday, a move for which no specific catalyst has been identified.

Growth in Revenue, Red Ink Below the Line

The third-quarter 2026 figures show why the two camps diverge. Revenue came in at $268 million, set against a net loss of $79.7 million, and the backlog stood at roughly $3.6 billion. For the fourth quarter, Rocket Lab guided to revenue of $270 million to $290 million while projecting an adjusted EBITDA loss of $14 million to $20 million.

Neutron, the medium-lift vehicle meant to move Rocket Lab beyond small satellites, is where the risk concentrates. Its debut has been pushed to 2027 after a manufacturing flaw in a tank component; Beck says a replacement part has been built, but tank qualification is still outstanding. The commercial case is nonetheless building — the company booked more than $515 million in Neutron launch contracts during the third quarter, covering eight missions for five satellite-constellation operators. Several of those were signed at a base price of $70 million per launch, and the Neutron backlog now totals 16 missions.

Read together, the two threads tell a consistent story rather than a contradictory one. Electron is a mature product with paying, returning customers; Neutron remains an unflown vehicle with a full order book and something still to prove. The 100th flight is evidence for the first. It says nothing about the second.

Ad

Rocket Lab Stock: New Analysis - 16 November

Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Rocket Lab analysis...

Disclaimer...
en | US7731211089 | ROCKET | boerse | 70521584 |